The first-of-its-kind invasive brain-computer interface (BCI) surgery accident insurance policy has officially filled a critical gap in China's clinical translation risk protection, yet the journey toward standardized, scalable coverage remains long. This landmark policy, underwritten by PICC Property and Casualty for the Second Affiliated Hospital of Zhejiang University School of Medicine, marks a significant milestone in the intersection of frontier medical technology and commercial insurance.
However, industry stakeholders must recognize that this inaugural policy is fundamentally a customized risk solution for a specific case, not a standardized insurance product ready for cross-institutional replication and large-scale deployment. The policy functions as a tailored protection scheme designed for a particular medical institution, a specific surgical approach, and a commercially approved implantable device, rather than a universally applicable offering for the national market.
The coverage precisely targets the unique risk scenarios inherent to invasive BCI procedures, including intraoperative cortical hemorrhage, brain tissue trauma, intracranial infection, electrode displacement or fracture, medical negligence, and long-term postoperative inflammatory rejection. The underwriting boundaries are tightly aligned with the existing clinical workflows, surgical standards, and approved implantable BCI devices at the Second Affiliated Hospital of Zhejiang University. At its core, this policy represents a dedicated risk mitigation arrangement for a single clinical scenario, lacking the universal underwriting rules, premium rate structures, and liability frameworks necessary for direct replication across hospitals and technology pathways.
Drawing on the development trajectory of mature surgical accident insurance in orthopedics, cardiovascular surgery, and neurosurgery, an innovative medical surgery insurance product must clear four essential hurdles to achieve standardization and scalable promotion. First, the industry must establish unified risk stratification standards that define clear risk classification rules for different technology pathways—including intracortical implantation, epidural implantation, and vascular interventional approaches—along with surgical difficulty gradients and device safety levels. Second, sufficient real-world data covering perioperative periods and mid-to-long-term follow-up must be accumulated to build a sample database capable of supporting actuarial pricing. Third, industry-wide standardized underwriting rules are needed to clarify patient preoperative eligibility criteria, qualifications for medical institutions and surgical teams, and compliance review checklists for implantable devices. Fourth, a mature and stable reinsurance risk diversification mechanism must be established to effectively absorb the large claims exposure pressure from high-risk policies.
None of these preconditions have been fully met given the current state of the industry, leaving BCI-related medical insurance in a pilot phase characterized by case-by-case negotiation and hospital-specific customization. The near-total absence of historical claims data represents the core challenge in pricing invasive BCI insurance. Unlike conventional neurosurgical procedures with decades of extensive clinical follow-up records, invasive BCI human application has a relatively short history, resulting in a severe shortage of statistical data on mid-to-long-term adverse events, complications, and device failures.
Under these real-world constraints, the industry currently adopts an underwriting and pricing logic that benchmarks against mature surgical procedures while applying weighted adjustments for multiple risk factors. Within this evaluation framework, the clinical experience of the surgical team and the hospital's disciplinary qualifications serve as the primary pricing anchor: the surgeon's cumulative experience with similar implantation procedures, historical complication rates, the hospital's neurosurgery department development level, and the supporting hardware conditions for stereotactic surgery are currently the most reliable risk assessment indicators. The industry predominantly uses complication data from deep brain stimulation (DBS) surgery—a clinically mature procedure—as the benchmark reference for building initial risk measurement models.
The safety and regulatory compliance of the implantable device emerge as the core variable determining the baseline risk coefficient for BCI surgery, serving as the primary hard criterion in insurance underwriting and pricing. During the underwriting review process, insurance companies must conduct comprehensive compliance verification of the implantable device, focusing on whether the device holds Class III medical device registration certification in China, possesses complete and compliant biocompatibility testing data, and compiling thorough records of adverse event rates, risk types, and management protocols from clinical trial phases. This rigorous vetting controls inherent device safety risks at the source. Currently, numerous BCI device brands are undergoing commercial and clinical pilot applications in China, each with significantly different technical architectures. Variations in electrode materials, implantation volumes, signal transmission methods, and power supply modes across manufacturers directly contribute to highly differentiated clinical risk profiles. Some devices are prone to intracranial tissue rejection, long-term electrode corrosion and degradation, signal transmission disruptions, and electrode displacement failures, with the probability and severity of these risks varying substantially—ultimately creating significant premium rate differences across devices and technology pathways.
Beyond inherent device risks, the patient's individual physiological baseline serves as a key supplementary factor for differentiated rate adjustments and precise individual risk control. During underwriting, insurance companies must conduct precise risk stratification of enrolled patients based on multiple core indicators, including age, systemic immune function, underlying cerebrovascular disease, severity of primary neurological damage, and prior surgical history. This allows for classification into high, medium, and low risk tiers, with tailored underwriting conditions, premium rates, and liability exemption clauses designed to mitigate the risk of excess claims arising from individual-specific factors. Simultaneously, the long-term risks of BCI surgery exhibit high concealment, and short-term clinical data cannot fully capture extended risk horizons. Postoperative long-term follow-up data becomes essential for refining actuarial models and calibrating risk expectations. By continuously tracking patients' clinical recovery over several years post-surgery, insurers can accurately assess the incidence patterns of delayed complications such as chronic intracranial infection, electrode failure, late-onset epilepsy, and neurological dysfunction—information that inversely optimizes actuarial assumptions and compensates for short-term data limitations, bringing risk pricing closer to real clinical scenarios.
Overall, the current underwriting evaluation system for BCI surgery insurance lacks a standardized template, relying entirely on manual specialist due diligence and case-by-case risk assessment. This results in cumbersome review processes, high labor and time costs, and persistently elevated marginal operating expenses—constituting the core operational barrier to achieving scale and batch underwriting in the industry. As clinical application accelerates, rapid replication of such insurance products becomes increasingly difficult. Invasive BCI surgery is not a single standardized procedure; different technology pathways—intracortical versus epidural implantation, wired versus wireless transmission—present vastly different levels of invasiveness, complication profiles, and long-term risks, rendering risk characteristics non-comparable across approaches. Changing hospitals, switching device manufacturers, or adjusting technology pathways requires complete re-evaluation of underwriting logic, with no direct applicability of the same policy's premium rates and liability terms. The greatest obstacle to scaling is the dual deficiency of unified industry risk standards and comprehensive lifecycle claims data: without a consensus risk rating system, the marginal cost of individual case underwriting remains prohibitively high; post-implantation long-term risk data spanning 3 to 10 years is virtually nonexistent, preventing insurers from forecasting long-term claims costs; and the substantial risk exposure of single policies combined with insufficient reinsurance appetite collectively constrains product expansion.
From a business model perspective, the paying entity will evolve in phases alongside technological commercialization. During clinical trials and initial deployment, BCI companies serve as the primary payers—ethical review requirements mandate risk protection for trial subjects, and companies need risk mitigation to accelerate technology adoption, consistent with the logic of clinical trial liability insurance for innovative medical devices. During early commercial promotion, payment shifts toward a company-patient co-sharing model, with companies subsidizing portions of premiums for customer acquisition while patients cover the remainder, and inclusive commercial health insurance can provide supplementary coverage. Once surgery enters routine clinical application, patients become the ultimate payers, with premiums incorporated into overall treatment costs as surgical accident insurance—a model consistent with current orthopedic and cardiac surgery accident insurance. In the long term, premiums becoming part of treatment costs is an inevitable trend; should BCI eventually be included in medical insurance reimbursement coverage, exploration of multi-party risk-sharing arrangements also becomes feasible.
Three core indicators signal when BCI insurance is ready to enter the standardized, scaled phase: first, the establishment of industry-wide risk classification and underwriting pricing rules that allow most property insurance companies to underwrite under uniform standards; second, coverage extending to mainstream hospitals conducting procedures nationwide and approved devices, with annual underwriting volume reaching thousands of cases or more; third, stabilization of the rate structure with claims ratios entering a predictable range and the reinsurance market forming mature acceptance mechanisms. If one were to identify the single most critical industry gap, it is the availability of sufficient sample sizes of full-lifecycle clinical risk and claims data. Insurance fundamentally operates on risk pricing based on the law of large numbers—all unified standards, underwriting rules, and rate systems must be built on adequate real-world data. Without data support, actuarial models cannot be implemented, and standardization remains impossible; what the industry calls unified risk standards are essentially products that emerge once data accumulation reaches a certain threshold.
The successful issuance of a single policy represents merely the first step toward maturity of the entire industrial risk protection system. Continued development of the BCI insurance sector cannot advance through the insurance industry alone; it urgently requires coordinated efforts among implantable device manufacturers, clinical medical institutions, insurance companies, and industry regulators to establish data-sharing mechanisms and jointly build unified risk standards. While strictly safeguarding patient privacy and data security compliance, stakeholders can leverage multi-party secure computation and desensitized data exchange to continuously accumulate information on adverse events, postoperative complications, and long-term device reliability. Only when sufficient long-term clinical data unlocks the underlying logic of risk pricing can commercial protection in the BCI field truly transition from case-by-case customization and niche pilot programs to standardized, inclusive coverage—establishing a robust market-based risk foundation for the long-term, high-quality, and scaled development of China's BCI future industry.